BofA lifts Schott Pharma to Neutral with EUR 27 target for Schott Pharma stock

Published on 10/18/2026 at 13:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q3 revenue reached EUR 281.8 million, up 8.3 percent at constant currencies. Schott Pharma stock closed at EUR 24.70 on Xetra on October 16, 2026.

Rating and operating figures

BofA moved Schott Pharma to Neutral on October 16, 2026.
Third-quarter revenue reached EUR 281.8 million, up 8.3 percent at constant currencies.
Schott Pharma stock closed at EUR 24.70 on October 16, 2026.

Börsenparkett in Frankfurt mit Kursdiagrammen und Pharma-Symbolen — SCHOTT Pharma (DE000A3ENQ51) zeigt das Frankfurter Börsenparkett mit Charts und kleinen Glasfläschchen-Symbolen auf großen Bildschirmen, Illustration mit AI erstellt.

Schott Pharma (ISIN DE000A3ENQ51) received a EUR 27.00 price target from BofA on October 16, 2026, when the bank upgraded its rating to Neutral from Underperform, as Markets Insider reported. The rating change puts the latest operating figures beside a more measured valuation view.

Third-quarter growth reached 8.3 percent

In the third quarter of fiscal 2026, Schott Pharma generated EUR 281.8 million in revenue, up 8.3 percent at constant currencies and 10.00 percent on a reported basis. EBITDA reached EUR 75.00 million, while the EBITDA margin was 26.8 percent, according to the Yahoo Finance transcript dated August 12, 2026.

The nine-month revenue total was EUR 769.8 million, representing growth of 4.4 percent at constant currencies. High-value solutions accounted for 59 percent of third-quarter revenue, giving the product mix a central role in the company's margin discussion.

What do the margins mean?

Profitability remains the main counterweight to the revenue increase. The third-quarter EBITDA margin of 26.8 percent was below 32.3 percent in the same quarter of fiscal 2025, while the nine-month margin was 26.7 percent versus 28.9 percent a year earlier. Management attributed the difference to lower utilization in Drug Delivery Systems, infrastructure costs and process optimization measures.

Schott Pharma confirmed fiscal 2026 guidance for revenue growth of 5 percent to 6 percent at constant currencies and an EBITDA margin of 27 percent to 28 percent. The company also expects capital expenditure of EUR 140 million to EUR 160 million for the fiscal year, according to the transcript.

Three dates frame the announcement

On July 8, 2026, Schott Pharma raised its fiscal 2026 revenue-growth guidance to 5 percent to 6 percent from 2 percent to 5 percent. On August 12, 2026, it reported third-quarter revenue of EUR 281.8 million. On October 16, 2026, BofA upgraded the rating to Neutral and set a EUR 27.00 target, as Markets Insider reported.

Upcoming company dates

The next listed company events are the BNP Midcap CEO Conference on November 17, 2026, and the publication of fiscal 2026 results on December 10, 2026, according to SCHOTT Pharma.

Stock remains below its yearly high

Schott Pharma closed at EUR 24.70 on Xetra on October 16, 2026. The same-day 52-week range was EUR 12.62 to EUR 26.05, leaving the closing price below the yearly high while the rating change supplied the latest market catalyst.

The further course of trading is shown by the continuously updated real-time quote of Schott Pharma stock.